

Successful Novel Treatment of Granuloma Faciale Using CO₂ Emulated Er:YAG Laser Ablation

Kilee Bayne, DO
Brandon E. Fornwalt, DO
Christopher F. Jonda, PAC
Adam D. Cash, MD

Summary: Granuloma faciale is a rare, benign inflammatory skin disease that has multiple medical treatment modalities due to its frequent unresponsiveness to treatment. This skin disease presents as a single, well-demarcated red-brown to violaceous, raised lesion, most commonly on the face, in middle-aged White men. Its etiology is unknown; sun exposure is thought to have some implications in its formation. Treatment modalities for granuloma faciale include topical therapy, intralesional injections, systemic therapies, phototherapy, lasers, cryotherapy, and surgical excision. In this article, we will highlight a rare case of granuloma faciale and its novel and successful treatment with a carbon dioxide emulated Er:YAG laser. (*Plast Reconstr Surg Glob Open* 2021;9:e3847; doi: [10.1097/GOX.0000000000003847](https://doi.org/10.1097/GOX.0000000000003847); Published online 7 October 2021.)

Granuloma faciale (GF) is a rare, benign, inflammatory skin disease that was first termed by Wigley in 1945, referring to the condition as an eosinophilic granuloma of the skin.¹ Clinically, GF presents as a red-brown to violaceous papule, or plaque, often with superficial telangiectasias, most commonly on the face.² The lesions may also present on the trunk, extremities, or in the nasal cavity.³ Due to the presenting location, it is hypothesized that sun exposure contributes to the formation of these plaques. Demographics of this disease include most commonly middle-aged White men, but it has also been shown to appear in children.¹ Although the exact etiology is unknown, it is commonly classified as an eosinophilic dermatosis.⁴ Diagnosis should be made with a biopsy and confirmed histopathologically. Histology of GF shows a dense mixed-cell infiltrate that extends into the papillary dermis but is separated from the epidermis by a narrow zone, referred to as the grenz zone.⁵ Typically, eosinophilic infiltrates are seen throughout, but not necessary for the diagnosis. Other histologic findings for GF include neutrophilic infiltration, telangiectasias, and vascular changes.⁵ Treatment of GF may be difficult with multiple medical modalities, including topical, systemic, and mechanical treatments. This article will discuss a case

of GF and its successful treatment with a carbon dioxide (CO₂) emulated Er:YAG laser.

CASE

A 60-year-old White man with no significant medical or social history presented to our clinic with a forehead lesion. He was previously seen by a dermatologist who had performed an incisional biopsy of the forehead lesion that confirmed the diagnosis of GF and was subsequently treated with two intralesional steroid injections, of unknown kind or dose, with minimal improvement of the lesion. The patient presented to our clinic, and upon evaluation, there was a midline upper forehead pigmented lesion (15 mm × 20 mm × 1 mm), variegated irregular border that was red to purple in pigment and slightly raised, as shown in [Figure 1](#). The patient's lesion was refractory to other medical therapy as detailed above, and the decision to undergo laser ablation therapy was made. The patient's treatment regimen included three total laser ablations using a CO₂ emulated Er:YAG laser: the Sciton Joule Laser (Palo Alto, Calif.) at treatment intervals of 9 months after the first ablation, and 6 months after the second ablation ([Table 1](#)). The patient also received 0.5 cm³ of intralesional triamcinolone injection (dose 40 mg/1 ml triamcinolone) diluted in equal parts of 1–100,000 epinephrine, in between the second and third laser treatments. The patient experienced some pain and hyperpigmentation 3 months after the first laser treatment, with significant improvement of the texture and coloration of the lesion after the second treatment, as shown in [Figure 2](#). After the third laser ablation treatment, the patient is very satisfied with the results, as shown in [Figure 3](#). The patient is now being observed every 3–6 months and continues with

From the Department of Plastic Surgery, St. Elizabeth Boardman Hospital, Boardman, Ohio.

Received for publication March 22, 2021; accepted July 28, 2021.

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 \(CCBY-NC-ND\)](#), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

DOI: [10.1097/GOX.0000000000003847](https://doi.org/10.1097/GOX.0000000000003847)

Disclosure: The authors have no financial interest to declare in relation to the content of this article.



Fig. 1. Pretreatment photograph of GF forehead lesion. This photograph is upon the patient's first visit to our clinic. The lesion measures about 15 mm × 20 mm × 1 mm.



Fig. 2. Post second laser treatment photograph of granuloma faciale forehead lesion. This photograph highlights the results of post-treatment of CO₂ emulated Er:YAG laser ablative therapy after two sessions.

Table 1. CO₂ Emulated Er:YAG Laser Ablation Settings, Sciton Joule Laser (Palo Alto, Calif.)

Er:Yag	2940 nm Wavelength
Contour TRL	
Ablate 50 μm	Coag 70
12.5 J/cm ²	50% overlap

The patient's lesion was treated with one pass over the lesion.

conservative measures of sun protection and cleansing of the area.

DISCUSSION

We present a case of the rare benign skin disease, GF, and will focus this discussion on the treatment strategy used. Treatment of GF can be difficult due to the persistent and recurrent nature of the disease. At times, it takes single or multitude modalities for resolution of GF, with the most common being topical therapy, intralesional injections, systemic therapies, phototherapy, lasers, cryotherapy, and/or surgical excision. In this case, we used CO₂ emulated Er:YAG laser therapy with much improvement of the patient's condition.

The standard approach to treating GF typically starts with topical therapy such as topical corticosteroids, or tacrolimus, followed by systemic drugs, and in case of failure, more invasive procedures.² A recently published systematic review of multiple treatment modalities of GF compared topical and systemic treatment options.² The article noted most success with tacrolimus 0.1% ointment twice daily with a trial of local dapsone gel for further option, followed by laser therapy and cryotherapy.² Cryotherapy is inexpensive and widely accessible but the effect is limited.² Systemic therapies such as systemic dapsone are well tolerated but have a risk of severe side effects and did not prove to be more effective than other therapies.² In this particular systematic review, they found that the use of lasers, preferably pulse-dye lasers, was the treatment of choice for drug-resistant GF.² Other studies have found success in treatment with KTP 532-nm lasers, and CO₂ lasers.²

In our case, we found success with using a CO₂ emulated Er:YAG laser. The patient had previously failed unknown topical therapies and was suffering from the aesthetic appearance of the lesion on his forehead. CO₂



Fig. 3. Post third/final laser treatment photograph of GF forehead lesion. This photograph highlights the results of posttreatment of CO₂ emulated Er:YAG laser ablative therapy after three sessions.

emulated Er:YAG laser therapy in three treatments was used and successfully reduced the size, color, and texture of the lesion. Both CO₂ and Er:YAG lasers are classified as ablative therapy which damage and remove most superficial layers of the skin, improving the appearance of skin after subsequent re-epithelization.⁶ The CO₂ laser is a versatile tool with many applications in ablative lasering.⁷ CO₂ lasers emit an invisible infrared beam at 10,600 nm, targeting intracellular and extracellular water, and vaporize tissues in a nonselective manner.^{2,7} CO₂ lasers generate the greatest depth of penetrance (about 5–15 times deeper than the Er:YAG laser); thus they are widely used for facial rejuvenation. Although they carry a higher risk of scarring or hypopigmentation, proper technical deployment of the CO₂ laser can help mitigate these side effects. The Er:YAG laser emits at a peak wavelength of 2940 nm, similar to the absorption peak of water at 3000 nm.⁶ Like the CO₂ laser, Er:YAG lasers also target water in the epidermal and papillary dermal layers of the skin, vaporizing water in the epidermal layer, creating a skin-peeling effect, and inducing thermal injury in the dermal layer, stimulating production of collagen, as well as improving and tightening of the skin.⁶ While CO₂ lasers may have a greater depth of penetrance, the wavelength of the Er:YAG is 12–18 times more efficiently absorbed by superficial water.⁶ In our case, we changed the settings on the Er:YAG laser to emulate the light and heat energy of a CO₂ laser for prospective deeper penetration. Typical

settings for an Er:YAG laser for a superficial skin ablation are 2940 nm, fluence of 2.5–5 J/cm², ablation of 15–20 μm, coagulation of 15 μm, short pulse duration of 250–1000 microseconds. We increased the fluence, ablation, and coagulation settings (as noted in Table 1) on our Er:YAG laser to emulate the ablative effects and thermal injury of a CO₂ laser. In our case, an Er:YAG laser was used due to its availability, and safety for in-office procedure, compared with a CO₂ laser. In review of the literature, there have been minimal reports of treating GF successfully with CO₂ laser ablation and no reports of using a CO₂ emulated Er:YAG laser. Similar reports of rhinophyma-like GF have documented success with using the CO₂ laser.⁸ Our case represents an innovative use and a positive outcome for treating GF with CO₂ emulated Er:YAG laser ablation therapy. When dealing with a case of GF that is resistant to multiple treatment modalities, CO₂ emulated Er:YAG laser ablative therapy should be considered due to its cosmetically pleasing outcome and low side-effect profile.

Kilee Bayne, DO

Department of Plastic Surgery, Bon Secours Mercy Health
 St. Elizabeth Boardman Hospital
 8401 Market St.
 Boardman, OH 44512
 E-mail: baynekilee@gmail.com

ACKNOWLEDGMENT

This study is exempt from IRB approval.

PATIENT CONSENT

The patient provided written consent for the use of his image.

REFERENCES

1. Al Dhafiri M, Kaliyadan F. Granuloma Faciale. [Updated 2020 Jul 10]. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available at <https://www.ncbi.nlm.nih.gov/books/NBK539832/>.
2. Lindhaus C, Elsner P. Granuloma faciale treatment: a systematic review. *Acta Derm Venereol.* 2018;98:14–18.
3. Ortonne N, Wechsler J, Bagot M, et al. Granuloma faciale: a clinicopathologic study of 66 patients. *J Am Acad Dermatol.* 2005;53:1002–1009.
4. Long H, Zhang G, Wang L, et al. Eosinophilic skin diseases: a comprehensive review. *Clin Rev Allergy Immunol.* 2016;50:189–213.
5. Peckruhn M, Elsner P, Tittelbach J. Eosinophilic dermatoses. *J Dtsch Dermatol Ges.* 2019;17:1039–1051.
6. Yumeen S, Khan T. *Laser Erbium-Yag Resurfacing*. Treasure Island, Fla.: StatPearls Publishing; 2020.
7. Krupa Shankar D, Chakravarthi M, Shilpakar R. Carbon dioxide laser guidelines. *J Cutan Aesthet Surg.* 2009;2:72–80.
8. Bakkour W, Madan V. Rhinophyma-like granuloma faciale successfully treated with carbon dioxide laser. *Br J Dermatol.* 2014;170:474–475.